|WHO Official: Swine Flu Epidemic Still In Early Stages |
Keiji Fukuda, WHO's Assistant Director-General for Health Security and Environment, said that given the size of the world's population, the new H1N1 virus is likely to spread for some time.
- WHO earlier estimated that as many as 2 billion people could become infected over the next two years — nearly one-third of the world population.
- Authorities in Britain say there were over 100,000 infections in England alone last week
- U.S. health officials estimate the United States has passed the 1 million case mark. Those figures dwarf WHO's tally of 130,000 confirmed cases worldwide since the start of the outbreak last spring.
- WHO announced that almost 800 people have died from the disease in the past four months. This is more than the H5N1 bird flu strain has killed in six years.
- The CDC said the number of Americans dying from swine flu over the next two years could range from 90,000 to several hundred thousand.
Swine Flu Virus Prevention:
Skinvisible’s DermSafe chlorhexidine hand sanitizer has been tested against many bacteria and viruses. It has been proven to kill / inactivate a number of influenza A viruses; including a strain of H1N1; the swine flu virus. Click here to read more...
Skinvisible in the News:
CBS News Station: Watch the television news cast featuring
SKINVISIBLE’S DERMSAFE AND HOW IT PROTECTS AGAINST H1N1
Read the newspaper article featuring
DERMSAFE MADE BY SKINVISIBLE
Note: DermSafe is currently not available for sale in the USA.
Skinvisible Pharmaceuticals, Inc. Skinvisible, Inc., through its wholly owned subsidiary, Skinvisible Pharmaceuticals, Inc., is an R&D pharmaceutical company that develops enhanced, patent protected dermatology and healthcare products including products to treat acne, skin cancers, eczema, fungal infections, inflammation, warts and dermatitis along with sunscreens, anti-aging products, alcohol-free hand sanitizing lotions, pre-surgical preparations, and various other medical treatments using its patented technology Invisicare®. Skinvisible's primary objective is to license these prescription and over-the-counter products into the $65 billion global dermatology market and other medical markets. Potential licensees include international and multi-national pharmaceutical, cosmetic, skincare and consumer goods companies seeking new products, product enhancements or life cycle management for their existing products. Click here to see current licensees.
The Technology: Invisicare® offers numerous benefits including binding products to the skin for 4 hours+ and more, while resisting wash-off and rub-off. It also enhances the efficacy of ingredients, reduces irritation and can reduce costs. Skinvisible has developed a portfolio of 25+ skincare products using Invisicare and also works directly with companies to enhance their products, especially ones coming off patent. Learn more at www.invisicare.com .
Intellectual Property: Skinvisible's value lies in its ability to continually generate new IP on dermatology and medical products formulated with Invisicare. Patent approvals are sought (in the U.S. and internationally) for all products developed. There are 4 patents approved, 9 U.S. patents pending in addition to 34 PCTs internationally, with many more to be filed. Some of these PCT patents cover up to five products. All patents with Invisicare are owned by Skinvisible. Click here to learn more about our patents.
The Opportunity: New product formulations are expensive and time intensive. Pharmaceutical companies are pursuing new or improved revenue streams along with protecting their own IPs. Invisicare allows companies to sell a patent-protected product that has been revitalized with new benefits, providing a new story to help combat generic competitors. An Rx dermatology product can generate $100+ million per year; many even more - that's why a pharmaceutical company's investment into an Invisicare formulated product is a very viable option.
| The Analyst Report |
February 2, 2009
February 25, 2008
July 21, 2008
July 31, 2009
Invisicare Approved For Additional US Patent - Further Intellectual Property Protection Enhances Skinvisible's Value
June 25, 2009
Skinvisible Receives Comprehensive Patent in China - Patent Protection For Invisicare Expands
May 4, 2009
Skinvisible in the News re H1N1
CLICK HERE TO READ ALL NEWS RELEASES